



Universiteit
Leiden
The Netherlands

Genetic, clinical and experimental aspects of restenosis : a biomedical perspective

Monraats, P.S.

Citation

Monraats, P. S. (2006, June 6). *Genetic, clinical and experimental aspects of restenosis : a biomedical perspective*. Retrieved from <https://hdl.handle.net/1887/4405>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4405>

Note: To cite this publication please use the final published version (if applicable).

I

GENERAL INTRODUCTION AND OUTLINE OF THE THESIS

Atherosclerosis is a type of arteriosclerosis. It comes from the Greek words *athe*ro (meaning gruel or paste) and *sclerosis* (hardness). Atherosclerosis is a disease of the arterial intima leading to the formation of fibrous (atheromatous) plaques and to stenosis of the lumen. It involves the proliferation of smooth muscle cells and the accumulation of lipids. Atherosclerosis affects large and medium-sized arteries. The type of artery and the localisation of the plaque vary between persons. In general, atherosclerosis is a slow, progressive disease that may start in childhood. In some people this disease progresses rapidly in their fourth decade. In others atherosclerosis becomes symptomatic when they are in their fifties or sixties. Atherosclerosis and its complications represent the dominant cause of mortality and morbidity in the Western world.⁽¹⁾

Modern therapy of atherosclerotic disease lowers plasma lipid level by statin treatment. However, when this therapy is insufficient, or for a patient with an acute coronary event, the therapy of choice has become Percutaneous Coronary Intervention (PCI). PCI is a safe and effective way to unblock coronary arteries. During this procedure, a catheter is inserted into an artery and guided forward into the coronary arteries of the heart. There, blocked arteries can be opened with a balloon positioned at the tip of the catheter.⁽²⁾ Initially, angioplasty was performed with balloon catheters only, but technical advances have been made and improved patient outcome has been achieved by placement of small metallic spring-like devices called “stents” at the site of previous blockage.^(3;4) The implanted stent serves as a scaffold that keeps the artery open. Angioplasty and stenting techniques are widely used around the world and provide an alternative option to medical therapy and bypass surgery for improving blood flow to the heart muscle. However, one of the main drawbacks of PCI is the occurrence of restenosis.^(5;6)

Pathogenesis of restenosis

Restenosis is commonly defined as the re-narrowing of the lumen to greater than 50% occlusion angiographically after PCI usually within three to six months.⁽⁷⁾ It is thought that the mechanism of this phenomenon is not mainly the progression of coronary artery disease, but rather the response of the body's immune system to the “injury” induced by angioplasty. At this point a repeat procedure may be needed. Compared to balloon angioplasty (BA) alone, having a chance of restenosis of 40%, stents reduce the chance of in-stent restenosis to 10-25%.^(4;8;9) Therefore, the majority of patients having angioplasty today are treated with stents.

Three distinct processes are involved in the pathogenesis of restenosis: vessel recoil and neointimal proliferation sometimes followed by early thrombus for

mation. The relative contribution of each of these depends on the type of injury. About three quarters of lumen loss after BA is the result of vessel recoil, and the rest is the result of neointimal proliferation.⁽¹⁰⁾ Coronary stenting virtually eliminates vessel recoil, and restenosis is largely the result of neointimal proliferation. When an artery is injured, deposition of platelets, leukocyte infiltration, proliferation of smooth muscle cells, deposition of extracellular matrix, and re-endothelialization occur. Growth factors and cytokines released by the blood cells involved stimulate the migration, growth, and multiplication of smooth muscle cells.^(7;11;12) A few years ago, a breakthrough in the prevention of restenosis was introduced by a new generation of “drug-eluting” stents. These stents release a particular drug that prevents scar tissue growth in the artery in which the stent is placed, and therefore reduce the occurrence of restenosis. Recent data have demonstrated that patients treated with drug-eluting stents have decreased incidence of restenosis compared to those who received bare metal stents.⁽¹³⁾

Risk factors for restenosis

Identification of patients at increased risk for restenosis may improve stratification of patients to individually tailored treatment. A number of clinical characteristics, such as advanced age, history of diabetes and several plasma markers, as well as angiographic details, such as the severity of coronary lesions, lesion length before the procedure, and minimal lumen diameter after the procedure have been shown to be associated with an elevated risk of restenosis after PCI.⁽¹⁴⁻¹⁸⁾ Thus far, however, these clinical factors have not been consistently found in different studies. Therefore, patients cannot be stratified with regard of risk for coronary restenosis based only upon clinical or procedural risk factors. There is evidence that genetic factors explain part of the excessive risk of restenosis after PCI independently of conventional clinical variables. For the same level of environmental risk, two individuals may have different probabilities of developing a cardiovascular event.⁽¹⁹⁾ Furthermore, in patients with multivessel disease, the incidence of restenosis of a second lesion was 2.5 times higher if PCI of the first lesion had led to restenosis, even after adjustments for known patient-related risk factors, including diabetes and hypertension.⁽²⁰⁾ However, the characterisation and identification of DNA variants (polymorphisms) responsible for this variation in individual susceptibility are complicated by the many factors involved in restenosis.

Genetic predisposition to restenosis

Today, a person's genetic background is considered in every aspect of clinical medicine, ranging from susceptibility to diseases, pathogenesis, and clinical outcome to diversity in responses to drug treatment (pharmacogenomics). The new panoramic look at the human genome has stimulated a massive search for clinically relevant genomic information, including single nucleotide polymorphisms (SNPs) that consist of substitutions of one nucleotide for another in a DNA sequence. Individual genomes are 99.9 percent identical, with only 0.1 percent of the genome showing polymorphisms.^(21;22) About 2 to 3 million SNPs have been found in exonic, intronic, regulatory, and intergenic regions. Almost all genes contain SNPs, but only a minority may have functional consequences because they either affect the expression level of a protein or predict an alteration of the amino acid sequence. Complexity increases at the protein level, since one human gene may produce up to five different proteins as a result of alternative splicing. Posttranslational modifications, such as assembly or glycosylation, further increase the diversity of proteins. Furthermore, environmental and other genetic factors may alter the phenotype that results from genetic abnormalities.

One of the main problems in the field of genetic association studies is the poor reproducibility.⁽²³⁾ In addition to true biological effects that influence the relationship of interest, a number of methodological and epidemiological factors may distort the results of genetic association studies, including definitions of patients and controls, population heterogeneity, and limited statistical power. These limitations have cast doubts on this type of study,⁽²⁴⁻²⁷⁾ and several biomedical journals have even adopted a policy of not publishing the results of association studies related to complex diseases. These difficulties, however, should be weighed against the potential benefits of genetic research. Because genetic predisposition does not fluctuate as do, for instance, plasma levels of a given risk factor, risk prediction based on genetic profiling would be a very effective approach. In addition, the studies of protein risk factors independent of their genetic determinants will likely result in an incomplete understanding of the pathophysiology. Recently, recommendations have been made for the design of future genetic association studies. The first recommendation concerned the adequacy of statistical power; the studies should have enough power to detect a relative risk of 1.25 or more. Recent evidence suggests that the large majority of genetic association studies performed thus far have been underpowered to detect the difference under study. A second important recommendation was that an observed genotype-disease association should be accompanied by supporting evidence from literature or from theoretical points of view for candidate variants to be involved in the disease. Furthermore, for each selected gene locus only

functional variants (i.e. variants that alter an amino acid or a transcription factor-binding element in a promoter region) should be included. Finally, the genotype must give a predictive value in carriers over and above established risk factors and the final data set should show no significant evidence for heterogeneity of risk effect.⁽²⁸⁾

Aim of this thesis

The GENetic DEterminants of Restenosis (GENDER) project was designed to study the association between various gene polymorphisms and clinical restenosis. Therefore, the aim of this thesis was to examine which polymorphisms, with its main focus on polymorphisms in genes involved in the inflammatory response, may contribute to the stratification of patients who are at increased risk of developing of restenosis. In addition, we also analysed different clinical factors.

GENDER study

The GENDER project is a multicenter follow-up study. Patients were eligible for inclusion if they were successfully treated for stable angina, non-ST-elevation acute coronary syndromes, or silent ischemia by PCI. Patients treated for acute ST elevation myocardial infarction (MI) were excluded. All patients were treated in four referral centers for interventional cardiology in the Netherlands (Academic Medical Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center and Academic Hospital Maastricht). The overall inclusion period lasted from March 1999 until June 2001, with inclusion intervals varying between the centers in order to include equal numbers of patients per center. In total, 3,104 consecutive patients were included in this prospective multicenter follow-up study.

The angiographic follow-up substudy

In addition to the clinical follow-up 480 patients also had a follow-up angiography at 6 months after PCI. Although the clinical endpoint depicts the clinical relevance of any risk factor more clearly, angiographic measurements quantify the restenosis process on a continuous scale. The angiograms have been studied in a Core laboratory to ensure standardized analysis (Heartcore, Leiden)

The protein substudy

In any genetic association study the ultimate proof of causality is the confirmation of an association with altered levels of gene-related proteins.^(29;30) However, to predict the development of restenosis in the individual patient plasma deter

minations may have no additive value, since basal (pre-PCI) plasma measurements of the gene product are not likely to reflect the genetically determined differences in reaction to a trauma such as PCI. However, to study the effects of several polymorphisms in the development of restenosis, plasma levels of selected gene products were measured by enzyme-linked immunosorbent assay in lipopolysaccharide-stimulated whole blood in a subpopulation of patients (N=69).

Mouse model of restenosis

To increase the understanding of the process of restenosis a mouse model can be used. In our study we made use of a well-defined mouse model. Diet-dependent ApoE*3-Leiden transgenic mice aged 8-10 weeks, weighing 25-30g, were fed a western-type diet 3 weeks prior to surgery, which diet was continued after surgery in order to maintain stable plasma cholesterol levels. The institutional committee on animal welfare of TNO-PG had approved the animal experiments. After 3 weeks on diet, mice were anaesthetized. The right femoral artery was prepared free and a 3 mm non-constricting polyethylene cuff (Portex, 0.40 mm inner diameter, 0.80 mm outer diameter) was placed loosely around it.

Animals were sacrificed at different time points after surgery (6, 24, 48 hours and 7 days after cuff implantaion), 4 mice for each time point. Both cuffed right femoral artery and untreated left femoral artery were prepared free, harvested and snap frozen. RNA was isolated and cDNA was synthesised using Ready-To-Go RT-PCR beads.⁽³¹⁻³³⁾

Perivascular cuff-placement result initially in adventitial injury, whereas PCI in patients primarily results in intimal injury. It is not certain to what extent these types of vascular injury differ in their reaction regarding vascular activation and the resulting intimal hyperplasia. However, the observation that local delivery of anti-restenotic agents using a drug-eluting polymer cuff in the mouse model inhibits neointima formation demonstrates that the model is useful to improve our understanding of the process of restenosis.⁽³⁴⁾

Focus of this thesis

Inflammatory responsiveness, which is highly genetically determined, plays a pivotal role in the process of restenosis.⁽³⁵⁻³⁸⁾ Many studies have demonstrated genetic influences upon the inflammatory response of an individual.^(39;40) Therefore, it is plausible that differences in genetic make-up of inflammatory genes between individuals may explain part of the risk of restenosis. Indeed, association studies have identified several candidate genes polymorphisms of which may predispose to restenosis, such as polymorphisms of the genes; stromely

sin-1, Interleukin-6, E-selectin, CD18, CD14 and Interleukin-1 receptor.^(35;36;41) Therefore, the main focus of this thesis is to examine genes and their polymorphisms involved in inflammatory pathways in patients of the GENDER population. We started by using validated multilocus genotyping assays to test several markers of inflammation and cardiovascular disease,^(42;43) in a large set of genes. Next, we continued genotyping polymorphisms with varying allele frequencies and distributed through the promoter, coding and 3'-untranslated regions of several candidate genes. Genes having polymorphisms that are significantly associated with restenosis were studied in the mouse model of restenosis, particularly to find out whether these genes were up or downregulated during the development of neointima. To further determine the functional effect of several polymorphisms examined, we performed whole-blood stimulation and tested effects on gene expression.

Outline of this thesis

This thesis focuses on clinical restenosis after PCI. Although we describe clinical factors involved in the development of restenosis, we focus mainly on genetic factors associated with restenosis. Chapter 2 reviews the genetic factors related to restenosis at the time we started genotyping. In chapter 3 we describe the GENDER population and the clinical factors associated with restenosis. Since diabetes is the strongest clinical risk factor of restenosis and is one of the five elements defining metabolic syndrome, we examined whether metabolic syndrome predicts the occurrence of restenosis in chapter 4. Chapter 5 presents the results of a gene-array study, in which we tested 48 polymorphisms in 34 genes involved in inflammation. In chapter 6, we present a promoter polymorphism of the fibrinogen gene, and in this study we also determined fibrinogen levels in the plasma of a subpopulation of patients. Polymorphisms in the lipoprotein lipase (LPL) gene have been extensively described and are known to have an effect on LPL activity. In chapter 7 we examined four different polymorphisms of the LPL-gene and their relation to restenosis. The goal of chapter 8 was to investigate the role of the TNF α gene in the restenosis process. TNF α is one of the key regulators of the inflammatory response and may therefore play an important role in the restenosis process. Chapter 9 explores the relationship between genetic variants in the caspase-1, PTPN22 and IL-1 γ genes and restenosis, which have been identified as important mediators in the inflammatory response and for caspase-1 also in apoptosis. Finally, since little is known about the involvement of anti-inflammatory cytokines in restenosis, chapter 10 examines the role of four different IL-10 polymorphisms in the development of restenosis. IL-10 is an important immunosuppressor cytokine, involved in the regulation of many aspects of immune responses.

Reference List

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet*. 1997;349:1498-1504.
2. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. *BMJ*. 2003;326:1137-1140.
3. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. *Lancet*. 1998;352:87-92.
4. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med*. 1987;316:701-706.
5. Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. *J Am Coll Cardiol*. 1988;12:616-623.
6. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. *Circulation*. 1988;77:361-371.
7. Lee MS, David EM, Makkar RR et al. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. *J Pathol*. 2004;203:861-870.
8. Agema WRP, Monraats PS, Zwinderman AH et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. *Eur Heart J*. 2004;25:1163-1170.
9. Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J Am Coll Cardiol*. 2003;41:1283-1288.
10. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. *Circulation*. 1996;94:35-43.
11. Ross R, Masuda J, Raines EW. Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. *Ann N Y Acad Sci*. 1990;598:102-112.
12. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115-126.
13. Roiron C, Sanchez P, Bouzamondo A et al. Drug-eluting stents: a meta-analysis of randomised controlled trials. *Heart*. 2005.
14. Petrovic D, Peterlin B. Genetic markers of restenosis after coronary angioplasty and after stent implantation. *Med Sci Monit*. 2005;11:RA127-RA135.
15. Sobel BE. Acceleration of restenosis by diabetes: pathogenetic implications. *Circulation*. 2001;103:1185-1187.

16. Stein B, Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. *Circulation*. 1995;91:979-989.
17. Bourassa MG, Lesperance J, Eastwood C et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol*. 1991;18:368-376.
18. Kereiakes D, Linnemeier TJ, Baim DS et al. Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials). *Am J Cardiol*. 2000;86:336-341.
19. Bauters C, Lamblin N, Amouyel P. [The genetics of multifactorial cardiovascular disease. How significant for the cardiologist?]. *Arch Mal Coeur Vaiss*. 2003;96:1127-1130.
20. Kastrati A, Schomig A, Elezi S et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. *Circulation*. 1998;97:2396-2401.
21. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. *Nature*. 2001;409:860-921.
22. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. *Science*. 2001;291:1304-1351.
23. Ioannidis JP, Ntzani EE, Trikalinos TA et al. Replication validity of genetic association studies. *Nat Genet*. 2001;29:306-309.
24. Hamsten A, Eriksson P. Thrombospondins and premature coronary artery disease: time to go beyond genotype-phenotype association studies. *Arterioscler Thromb Vasc Biol*. 2003;23:6-7.
25. Hegele RA. SNP judgments and freedom of association. *Arterioscler Thromb Vasc Biol*. 2002;22:1058-1061.
26. Jones A, Montgomery H. The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies? *Eur Heart J*. 2002;23:1071-1074.
27. Taegtmeyer AB, Barton PJ. SNP at your own risk. *Eur Heart J*. 2002;23:692-694.
28. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? *Arterioscler Thromb Vasc Biol*. 2004;24:628-636.
29. Lardenoye JH, Delsing DJ, de Vries MR et al. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. *Circ Res*. 2000;87:248-253.
30. Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. *J Clin Invest*. 1998;101:1225-1232.

31. Quax PH, Lamfers ML, Lardenoye JH et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. *Circulation*. 2001;103:562-569.
32. Pires NM, van der Hoeven BL, de Vries MR et al. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. *Biomaterials*. 2005;26:5386-5394.
33. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. *Nat Genet*. 1995;11:241-247.
34. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. *N Engl J Med*. 1998;338:122-124.
35. De Maat MP, Jukema JW, Ye S et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. *Am J Cardiol*. 1999;83:852-856.
36. Kastrati A, Koch W, Berger PB et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. *J Am Coll Cardiol*. 2000;36:2168-2173.
37. Monraats PS, Agema WRP, Jukema JW. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. *Pathol. Biol. (Paris)*. 2004;52:186-195.
38. Sharif F, Daly K, Crowley J et al. Current status of catheter- and stent-based gene therapy. *Cardiovasc Res*. 2004;64:208-216.
39. Bidwell J, Keen L, Gallagher G et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. *Genes Immun*. 2001;2:61-70.
40. Verschuur M, Van Der Beek MT, Tak HS et al. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. *Blood Coagul Fibrinolysis*. 2004;15:399-404.
41. Barcellos LF, Begovich AB, Reynolds RL et al. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. *Ann Neurol*. 2004;55:793-800.
42. Cheng S, Grow MA, Pallaud C et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. *Genome Res*. 1999;9:936-949.